Impel NeuroPharma has announced the resignation of Jon Congleton as President and CEO; Adrian Adams, who was appointed as Impel’s Chairman of the Board of Directors in January 2020, will now add the CEO role. Adams has previously served as CEO of a number of pharmaceutical companies, including Aralez, Auxilium, Neurologix, Inspire Pharmaceuticals, Sepracor, and Kos.
Earlier this year, Impel named Sheena K. Aurora as VP of Medical Affairs, Migraine Franchise, to direct the medical affairs strategy for Impel’s INP104 intranasal intranasal dihydroergotamine (DHE) for the treatment of acute migraine. A pivotal Phase 3 study of INP104 has been completed, and results are expected to be announced by mid-2020.
Adams commented, “Impel’s product pipeline and novel technology platform has the ability to positively impact the lives of patients living with serious CNS disorders. I look forward to working with the talented team to advance our late-stage programs and to deliver the full potential of our novel, differentiated investigative therapeutic products. This is a pivotal time for the company with a number of significant upcoming milestones, including Phase 3 data, a planned new drug application (NDA) filing, and pre-launch commercialization planning for our lead candidate, INP-104, for acute migraine.”
Read the Impel NeuroPharma press release.
